Reporting quality of randomized controlled trials evaluating non-vitamin K oral anticoagulants in atrial fibrillation: a systematic review

Table 3 Factors associated with key elements of the CONSORT guidelines

Characteristics	Mean OQS (95% CI)	Standardized Coefficients		Standardized Coefficients Beta	t	Estimate 95% CI		p-vale
Characteristics	Mean OQS (95% CI)	B	SE	Standardized Coefficients Beta	t	Lower	Upper	p-vale
Constant		8.35	2.41		3.47	3.53	13.18	0.00
Year of publication		0.04	1.03	0.00	0.04	-2.03	2.10	0.97
2001–2010	15.12 (10 to 17.5)
2011–2022	13.94(8.5 to 20)
Region in which trials were		-0.74	0.55	-0.14	-1.33	-1.85	0.37	0.19
Asia	13.94 (9.5 to 18.5)
Europe and North America	13.92 (8.5 to 20)
Sources of trial funding		0.59	0.25	0.24	2.34	0.08	1.09	0.02
Not reported	13.51 (10 to 18)
Industry	13.71 (8.5 to 20)
Government and industry	13.82 (11 to 16.5)
Government	14.09 (9.5 to 18.5)
Journal impact factor		1.07	0.36	0.36	2.95	0.34	1.79	0.01
< 4	13.13 (8.5 to 17)
4–10	13.86 (9.5 to 17.5)
≥ 10	14.08 (12 to 20)
Sample size		-0.04	0.34	-0.01	-0.11	-0.72	0.65	0.91
≤ 200	13.60 (8.5 to 17)
200–400	13.59 (11 to 17.5)
≥ 400	14.13 (9.5 to 20)
International collaboration		2.18	0.62	0.42	3.54	0.95	3.42	< 0.01
No	13.17 (8.5 to 20)
Yes	13.94 (9.5 to 18.5)

ISSN: 1471-2261